Esomeprazole Magnesium D-r Capsules Usp 20mg (20mg 30s)
Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 68788-4014
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 68788-4014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Table-3 (Table 3)
Table-4 (Table 4)
This information discusses the impact of CYP2C19 or CYP3A4 inducers on esomeprazole exposure, specifically highlighting the decreased exposure of esomeprazole when used concomitantly with strong inducers such as St. John's Wort and rifampin. It also mentions increased exposure of esomeprazole when taken with Voriconazole and advises on dose adjustments for patients with Zollinger-Ellison syndrome who may require higher doses. The text emphasizes the importance of consulting prescribing information for specific drugs such as Ritonavir-containing products.*
Esomeprazole-structure (Esomeprazole Structure)
Esomeprazole-fig2 (Esomeprazole Fig2)
This text provides information on the percentage of maintenance for different doses of Esomeprazole Magnesium and placebo over a certain period. The doses mentioned are 40mg, 20mg, and 10mg, with the number of participants (N) for each dose also given. The data may refer to a study or trial evaluating the effectiveness of Esomeprazole Magnesium compared to a placebo in maintaining certain characteristics or conditions over a period of time.*
Esomeprazole-fig3 (Esomeprazole Fig3)
This text provides information about the percent of individuals who maintained their condition with different doses of Esomeprazole Magnesium (40 mg, 20 mg, 10 mg) and a placebo. Data is presented for each group (N = number of participants).*
Esomeprazole-fig4 (Esomeprazole Fig4)
Not available.*
Esomeprazole-fig5 (Esomeprazole Fig5)
This text provides information about the percentage of patients who are symptom-free when taking Esomeprazole Magnesium in 20mg or 40mg doses. It references diary days 14, 21, and 28. The specific details or context of the symptom-free percentage are not available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
